NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
https://doi.org/10.15829/1560-4071-2015-2-115-122
Abstract
The article takes into consideration practical issues of novel oral anticoagulants (factor Xa inhibitors) usage with the aim of prevention of thromboembolic complications in nonvalvular atrial fibrillation.
A clinical case presented the patient with this pathology under high risk of thromboembolic complications with several years follow-up.
About the Authors
D. A. Itkin
Russian Medical Academy of Postgraduate education of the Healthcare Ministry, Moscow
Russian Federation
Russian Federation
Yu. N. Moiseeva
CCH n. a. S. P . B otkin, Moscow
Russian Federation
Russian Federation
I. A. Libov
Russian Medical Academy of Postgraduate education of the Healthcare Ministry, Moscow
Russian Federation
Russian Federation
References
1. Wyse DG, Waldo AL, DiMarco JP, et al, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation.N Engl J Med. 2002 Dec 5; 347(23):1825-33.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370-5.
3. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373:155-66.
4. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160: 967-73.
5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114:e257–354 & Eur Heart J 2006; 27: 1979-2030.
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
7. Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-52.
8. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-92.
9. Matchar DB. Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. Card Electrophysiol Rev 2003; 7: 379-81.
10. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458-63.
11. Nichol MB, Knight TK, Dow T, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008; 42: 62-70.
12. S hen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-15.
13. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
14. Apenteg PN, Murrary ET, Holder R, et al, UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovascular Disorders. 2013, 13:31. DOI: 10.1186/1471-2261-13-31.
15. P atel MR, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. The New England Journal of Medicine 2011; 365: 10: 883-91.
16. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
17. Haas S, Bode C, Norrving B, et al. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular Heart and Risk Management 2014: 10 101-14.
18. P atel MR, Kenneth MD, Mahaffey W, et al, ROCKET AF Steering Committee for the ROCKET AF Investigators Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-91.
19. S tangier J. Dabigatran etexilate is now approved for clinical use in stroke prevention in atrial fibrillation in certain countries. Clin Pharmacokinet 2008; 47: 285-95.
20. Mega JL, et al. “Rivaroxaban in Patients with Recent Acute Coronary Syndrome”. The New England Journal of Medicine. 2012. 366(1): 9-19.
Review
For citations:
Itkin D.A., Moiseeva Yu.N., Libov I.A. NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2015;(2):115-122. (In Russ.) https://doi.org/10.15829/1560-4071-2015-2-115-122
Views:
1082
Email this article 